Previous close | 3.1000 |
Open | 3.1000 |
Bid | 2.8000 |
Ask | 3.0000 |
Strike | 20.00 |
Expiry date | 2024-07-19 |
Day's range | 3.1000 - 3.1000 |
Contract range | N/A |
Volume | |
Open interest | 150 |
PALO ALTO, Calif., May 07, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights Guardant Health’s leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies in the industry.
Besides Wall Street's top -and-bottom-line estimates for Guardant Health (GH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.